DNTH

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York dedicated to developing novel monoclonal antibody therapies for severe autoimmune and inflammatory diseases. The firm boasts a strong pipeline aimed at addressing significant unmet medical needs through its proprietary drug development programs. By advancing innovative solutions and progressing through critical clinical trials, Dianthus is positioning itself at the forefront of precision medicine, making it an attractive opportunity for institutional investors interested in pioneering advances within the biopharmaceutical sector.